(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.
Avalo Therapeutics's earnings in 2026 is -$100,333,000.On average, 16 Wall Street analysts forecast AVTX's earnings for 2026 to be -$146,619,027, with the lowest AVTX earnings forecast at -$187,104,306, and the highest AVTX earnings forecast at -$99,671,335. On average, 16 Wall Street analysts forecast AVTX's earnings for 2027 to be -$143,025,818, with the lowest AVTX earnings forecast at -$186,578,732, and the highest AVTX earnings forecast at -$92,409,834.
In 2028, AVTX is forecast to generate -$179,204,608 in earnings, with the lowest earnings forecast at -$237,559,399 and the highest earnings forecast at -$112,622,977.